Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Hewes L. Becker

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/11/2021

3. Issuer Name and Ticker or Trading Symbol

Blueprint Medicines Corp [BPMC]

(Last) (First) (Middle)

C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Medical Officer /

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	17500 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	6/1/2030	Common Stock	35000	$66.24	D

Explanation of Responses:
(1)	The number reported includes 17,500 restricted stock units previously granted to the Reporting Person.
(2)	This option was granted on June 1, 2020. This option vested with respect to 25% of the shares underlying the option on June 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter.

Remarks:
Exhibit 24 - Limited Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Hewes L. Becker C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE, MA 02139			Chief Medical Officer

Signatures
/s/ Christopher Frankenfield, Attorney-in-Fact		1/19/2021
^**Signature of Reporting Person		Date

Grafico Azioni Blueprint Medicines (NASDAQ:BPMC)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Blueprint Medicines (NASDAQ:BPMC)
Storico
Da Lug 2023 a Lug 2024

BPMC Blueprint Medicines Corporation